More than five years after an initial FDA approval, Novartis is touting positive trial results for its radiotherapy Lutathera as a first-line therapy against the rare cancer that killed Apple ...
Radiopharmaceuticals, along with cell and gene therapy, is one of the advanced drug platforms Novartis has pegged for long-term growth. But that ambition has hit a small setback. Lutathera, the first ...
Basel, June 3, 2021 — Novartis today reported the final analysis from the NETTER-1 phase III study comparing treatment using Lutathera® (INN: lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 ...
The diagnosis of NETs is often delayed and approximately 10% to 20% of pediatric patients are diagnosed with metastatic disease. The approval was based on the NETTER-P trial, which evaluated Lutathera ...
Lutathera is a prescription drug that’s used to treat certain rare tumors. It’s given as an intravenous (IV) infusion by a healthcare professional. Lutathera is used in adults and certain children to ...
Novartis AG NVS released topline data from the Phase 3 NETTER-2 trial with Lutathera, a radioligand therapy (RLT) for advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Radioligand ...
Midgut neuroendocrine tumors are a rare type of cancer that develops in the small intestine and colon. Roughly 12,000 people are diagnosed with this disease each year. In January, the United Stated ...
Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results